代表论文（第一或通讯作者）、参编著作：
1. Hui K, Wu SQ, Yue YY, Gu YN, Guan B, Wang XY, Hsieh JT, Chang LS, He DL, Wu KJ. RASAL2 inhibits tumor angiogenesis via p-AKT/ETS1 signaling in bladder cancer. Cell Signal, 2018 Aug; 48: 38-44. (SCI收录，IF=3.487，通讯作者)
2. Wu KJ, Pei XQ, Tian G, Jiang YM, Wu DP, Fan JH, He DL. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Asian J Androl, 2018 Mar-Apr;20(2):173-177.（SCI收录，IF=3.259）
3. Wang B*, Lo UG*, Wu KJ*, Kapur P, Liu XY, Huang J, Chen W, Hernandez E, Santoyo J, Ma SH, Pong RC, He DL, Chen YQ, Hsieh JT. Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer. Int J Cancer, 2017, Nov 15;141(10):2121-2130.（SCI收录，IF=7.360，共同第一作者）
4. Pei XQ, He DL, Tian G, Lv W, Jiang YM, Wu DP, Fan JH, Wu KJ. Prognostic factors of first-line docetaxel treatment in castration-resistant prostate cancer: roles of neutrophil-to-lymphocyte ratio in patients from Northwestern China. Int Urol Nephrol, 2017, 49(4): 629-635.（SCI收录，IF=1.692，通讯作者）
5. Hui K, Gao Y, Huang J, Xu S, Wang B, Zeng J, Fan JH, Wang XY, Yue YY, Wu SQ, Hsieh JT, He DL, Wu KJ. RASAL2, a RAS GTPase activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Cell Death Dis, 2017, 8: e2600.（SCI收录，IF=5.638，通讯作者）
6. Wang B, Huang J, Zhou JC, Hui K, Xu S, Fan JH, Li L, Wang XY, Hsieh JT, He DL, Wu KJ. DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein. Cell Signal, 2016, 28: 1623–1630.（SCI收录，IF=3.487，通讯作者）
7. Huang J, Wang B, Hui K, Zeng J, Fan JH, Wang XY, Hsieh JT, He DL, Wu KJ. miR-92b targets DAB2IP to promote EMT for bladder cancer migration and invasion. Oncol Rep, 2016, 36: 1693-1701.（SCI收录，IF= 2.976，通讯作者）
8. Zhou JC*, Luo JH*, Wu KJ*, Kapur P, Yun EJ, Pong RC, Du YF, Wang B, Authement C, Hernandez E, Yang JC, Cha TL, Wu HC, Margulis V, Lotan Y, Brugarolas J, He DL, Hsieh JT. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene, 2016; 35(35): 4663-74.（SCI收录，IF=6.854，共同第一作者）
9. Zhou JC, Zhu GD, Huang J, Li L, Du YF, Gao Y, Wu DP, Wang XY, Hsieh JT, He DL, Wu KJ. Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: a novel potential therapeutic target. Cancer Lett, 2016 Jan 28, 370(2):313-323.（SCI收录，IF=6.491，通讯作者）
10. Wu KJ, Wang B, Chen YL, Zhou JC, Huang J, Hui K, Zeng J, Zhu JN, Zhang K, Li L, Guo P, Wang XY, Hsieh JT, He DL, Fan JH. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling. Cell Signal, 2015 Sep 26;27(12):2515-2523. (SCI收录，IF=3.487)
11. Zhou J, Ning Z, Wang B, Yun EJ, Zhang T, Pong RC, Fazli L, Gleave M, Zeng J, Fan J, Wang X, Li L, Hsieh JT, He D, Wu K. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis. Cell Death Dis, 2015, Oct 29;6:e1955.（SCI收录，IF=5.638，通讯作者）
12. Wei JH*, Haddad A*, Wu KJ*, Zhao HW, Kapur P, Zhang ZL, Zhao LY, Chen ZH, Zhou YY, Zhou JC, Wang B, Yu YH, Cai MY, Xie D, Liao B, Li CX, Li PX, Wang ZR, Zhou FJ, Shi L, Liu QZ, Gao ZL, He DL, Chen W, Hsieh JT, Li QZ, Margulis V, Luo JH. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nat Commun, 2015 Oct 30;6:8699.（SCI收录，IF=12.353，共同第一作者）
13. Zhou JC, Deng Z, Chen YL, Gao Y, Wu DP, Zhu GD, Li L, Song WB, Wang XY, Wu KJ#, He DL#. Overexpression of FABP7 promotes cell growth and predicts poor prognosis of clear cell renal cell carcinoma. Urol Oncol, 2015, 33: 113.e9–113.e17.（SCI收录，IF=3.397，共同通讯作者）
14. Zhou JC*, Wu KJ*, Gao DX, Zhu GD, Wu DP, Wang XY, Chen YL, Du YF, Song WB, Ma ZK, Authement C, Saha D, Hsieh JT, He DL. Reciprocal regulation of hypoxia-inducible factor 2α and GLI1 expression associated with the radio-resistance of renal cell carcinoma. Int J Radiat Oncol Biol Phys, 2014; 90(4):942-951.（SCI收录，IF= 5.554，共同第一作者）
15. Ma YM*, Wu KJ*, Dang Q, Shi Q, Gao Y, Guo P, Xu S, Wang XY, Gong YG, He DL. Testosterone regulates keratin 33B expression in rat penis growth through androgen receptor signaling. Asian J Androl, 2014; 16(5):817-823.（SCI收录，IF=3.259，共同第一作者）
16. Wu KJ, Ning ZY, Zhou JC, Wang B, Fan JH, Zhu JC, Wang XY, Hsieh JT, He DL. 2'-hydroxyflavanone inhibits prostate tumor growth through inactivating AKT/STAT3 signaling and inducing cell apoptosis. Oncol Rep, 2014; 32(1):131-138.（SCI收录，IF= 2.976）
17. Ma YM*, Wu KJ*, Ning L, Zeng J, Kou B, Xie HJ, Ma ZK, Wang XY, Gong YG, He DL. Relationship between androgen receptor CAG repeat polymorphism, sex hormone and penile length in Han adult men from China: a cross-sectional study. Asian J Androl, 2014; 16(3):478-81.（SCI收录，IF=3.259，共同第一作者）
18. Wu K, Liu J, Tseng SF, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G, Sun X, Oz OK, Min W, Alexandrakis G, Yang CR, Hsieh CL, Wu HC, He D, Xie D, Hsieh JT. The role of DAB2IP in androgen receptor activation during prostate cancer progression. Oncogene, 2014 Apr 10;33(15):1954-63. (SCI收录，IF=6.854).
19. Wu K, Ning Z, Zeng J, Fan J, Zhou J, Zhang T, Zhang L, Chen Y, Gao Y, Wang B, Guo P, Li L, Wang X, He D. Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial-mesenchymal transition and stemness. Cell Signal, 2013 Dec;25(12):2625-33. (SCI收录，IF=3.487)
20. Wu K, Zeng J, Zhou J, Fan J, Chen Y, Wang Z, Zhang T, Wang X, He D. Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development. Urol Oncol, 2013 Nov;31(8):1751-60. (SCI收录，IF=3.397)
21. Wu K, Xie D, Zou Y, Zhang T, Pong RC, Xiao G, Fazli L, Gleave M, He D, Boothman DA, Hsieh JT. The mechanism of DAB2IP in chemo-resistance of prostate cancer cells. Clin Cancer Res, 2013 Sep 1;19(17):4740-9. (SCI收录，IF=10.199).
22. Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou J, Li L, Chen Y, Zhang T, Wang X, Hsieh JT, He D. PI3K/Akt to GSK3β/β-catenin Signaling Cascade Coordinates Cell Colonization for Bladder Cancer Bone Metastasis through Regulating ZEB1 Transcription. Cell Signal, 2012 Dec;24(12):2273-82. (SCI收录，IF=3.487)
23. Wu K, Gore C, Yang L, Fazli L, Gleave M, Pong RC, Xiao G, Zhang L, Yun EJ, Tseng SF, Kapur P, He D, Hsieh JT. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Mol Endocrinol, 2012 Sep;26(9):1496-507. (SCI收录，IF=3.678，封面文章)
24. Wu K, Zeng J, Li L, Fan J, Zhang D, Xue Y, Zhu G, Yang L, Wang X, He D. Silibinin reverses epithelial to mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol Rep, 2010 Jun;23(6):1545-52.（SCI收录，IF= 2.976）
25. Wu KJ, Zeng J, Zhu GD, Zhang LL, Zhang D, Li L, Fan JH, Wang XY, He DL. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing Vimentin and MMP-2 Expression. Acta Pharmacol Sin, 2009 Aug;30(8):1162-8.（SCI收录，IF=3.562）
26. Yun EJ, Wu KJ, Tsai YS, Xie DX, Hsieh JT. The functional role of DAB2IP, a homeostatic factor, in prostate cancer. Prostate Cancer: Biochemistry, Molecular Biology and Genetics (Editor: Donald J. Tindall). Chapter, 2013, Springer Science Publishers.
27. He DL, Li L, Wu KJ. Update of the most recent advances in the treatment of metastatic castration-resistant prostate cancer. Prostate Cancer Cells: Detection, Growth and Treatment (Editor: Zongbing You). Chapter, 2012, Nov. Nova Science Publishers.
